An in-silico Approach for the Retrieval of Potential anti Beta-secretase Inhibitor abate Alzheimer Disease
16
Views
54
Downloads
Alzheimer's disease (AD) is a neurodegenerative disorder and still posing challenges to the scientific community for designing and developing a novel drug. The in-silico drug design approach dispenses tools for reducing time, cost, and energy associated with reducing the ligands number for experimental and in-vivo assays. An extensive literature survey was performed for the collection of bioactive phytochemicals. After that, a structure-based drug design approach was deployed to explore potential inhibitory phytochemicals against β- secretase for the treatment of AD. The molecular docking and pharmacokinetics analysis was performed. The present research has led to the unraveling of the poof potential of phytochemicals against β- secretase. The sanjoinenine, luteolin, and vaticinate phytochemicals are identified as potential lead molecules for in-vivo studies.
<?xml version="1.0"?>